Clinical Trials on Exostoses, Multiple Hereditary in Finland

Total 265 results

Sanofi

Active, not recruiting

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

Secondary Progressive Multiple Sclerosis

United States, Argentina, Belgium, Canada, Czechia, France, Germany, Greece, India, Israel, Netherlands, Norway, Portugal, Turkey, United Kingdom, Japan, Austria, Bulgaria, China, Denmark, Finland, Italy, Lithuania, Poland, Romania, Russian... and more
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple Myeloma

United States, Saudi Arabia, Puerto Rico
Bayer

Completed

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients

Multiple Sclerosis, Relapsing-Remitting

Belgium, Israel, Sweden, United States, France, Switzerland, Ireland, Canada, Australia, Brazil, Austria, Poland, Germany, Hungary, Netherlands, Russian Federation, Spain, Argentina, Slovenia, Greece, Finland, Denmark, Ukraine, Italy, L... and more
Amgen

Terminated

A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

Relapsed or Refractory Multiple Myeloma

United States
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Multiple Sclerosis, Relapsing-Remitting

Belgium, United Kingdom, Australia, Netherlands, Ireland, Norway, Turkey, Estonia, Denmark, Germany, Italy, Spain, Switzerland, France, Finland, Sweden, Czechia
European Society for Blood and Marrow Transplantation

Completed

Stem Cell Translpantation in Multiple Myeloma

Multiple Myeloma

Austria, Denmark, Germany, Finland, Canada, Sweden, Norway, France, Italy, United Kingdom, Turkey
Novartis

Completed

Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

Relapsing Multiple Sclerosis

Germany, Italy, Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, Greece, Hungary, Ireland, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovakia, Spain, Sweden, Switzerland, Turkey, United Kingdom
Sanofi

Terminated

Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta (TERACLES)

Multiple Sclerosis Relapse

Spain, Germany, Sweden, Canada, Austria, Korea, Republic of, Russian Federation, Greece, Hungary, Italy, Belgium, Slovakia, Tunisia, France, Australia, United States, Argentina, Brazil, Chile, Colombia, Denmark, Estonia, Finland, Lith... and more
Oncotherapeutics
Amgen

Terminated

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Multiple Myeloma

United States
Jaeb Center for Health Research
Foundation Fighting Blindness

Recruiting

Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants (Uni-Rare)

Retinitis Pigmentosa | Inherited Retinal Degeneration

United States, United Kingdom, France, Finland, Israel, Netherlands, Switzerland, Australia, Canada, Brazil, Mexico
AbbVie

Terminated

A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma

Cancer | Multiple Myeloma (MM)

United States, Australia, France, Israel, Japan, Spain, Taiwan
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

United States, Belgium, Czechia, Russian Federation, Serbia, Spain, Italy, Netherlands, Finland, Estonia, Brazil, France, Germany, Poland, Switzerland, Ukraine, Peru, Argentina, Lithuania, Slovakia, Portugal, Australia, Hungary, Tunisia, Bulgar... and more
Sequenom, Inc.

Completed

Noninvasive Screening for Affected Pregnancies: Assay Development & Optimization in Affected Pregnancies (CHARMM-AP)

Down Syndrome | Aneuploidy

United States
Biogen
Elan Pharmaceuticals

Completed

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States, Germany, Austria, Belgium, France, Israel, Italy
Sanofi

Active, not recruiting

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) (GEMINI 1)

Relapsing Multiple Sclerosis

Spain, United States, Mexico, Japan, Austria, Belarus, Bulgaria, Canada, China, Czechia, Denmark, Estonia, Finland, Germany, Italy, Lithuania, Poland, Romania, Russian Federation, Sweden, Taiwan, Turkey, Ukraine, Hong Kong
Sanofi

Completed

Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis (TEMSO)

Multiple Sclerosis

Ukraine, Russian Federation, Estonia, Czech Republic, Denmark, Finland, France, Turkey, United Kingdom, United States, Portugal, Austria, Canada, Chile, Germany, Italy, Netherlands, Norway, Poland, Sweden, Switzerland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. (ASCLEPIOS II)

Relapsing Multiple Scelrosis

United States, Austria, Belgium, Croatia, Germany, Taiwan, Canada, Czechia, Spain, Argentina, Australia, Peru, South Africa, United Kingdom, Bulgaria, Latvia, Lithuania, Russian Federation, India, Portugal, Italy, Turkey, Finland, France and more
Pfizer
Bristol-Myers Squibb

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Multiple Myeloma

United States, Canada
NCIC Clinical Trials Group

Completed

Combination Chemotherapy in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

Canada, United States
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (FENhance)

Relapsing Multiple Sclerosis

United States, Mexico, Hungary, China, Germany, Italy, Peru, Poland, Portugal, Russian Federation, Spain, Switzerland, Ukraine, Tunisia, Netherlands, Argentina, Georgia, Hong Kong, Kenya, Dominican Republic, Finland, North Macedonia, Serb...
Biogen

Completed

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab (STRATIFY-2)

Relapsing Multiple Sclerosis

United States, Puerto Rico
Brown University

Recruiting

Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA

Arthritis | Chronic Pain | Chronic Low-back Pain | Irritable Bowel Syndrome | Fibromyalgia | Acute Pain | Trauma, Multiple | Neuropathic Pain | Temporomandibular Joint Disorders | Post Operative Pain | Chronic Pain Syndrome | Chronic Shoulder Pain | Painful Diabetic Neuropathy | Chronic Migraine | Painful Bladder Syndrome and other conditions

United States
Novartis Pharmaceuticals

Completed

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Secondary Progressive Multiple Sclerosis

China, Germany, United States, Romania, Italy, Austria, Belgium, Czechia, Spain, Australia, Canada, France, Israel, Switzerland, Bulgaria, Hungary, Netherlands, United Kingdom, Estonia, Latvia, Lithuania, Russian Federation, Turkey, J... and more
UCB Pharma
Biogen

Terminated

Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Multiple Sclerosis

United States, France, Germany, Spain, Canada, Netherlands, Belgium, Hungary, Sweden, United Kingdom, Finland
Genzyme, a Sanofi Company
Bayer

Completed

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

Multiple Sclerosis, Relapsing-Remitting

Netherlands, Spain, Germany, Israel, United Kingdom, Canada, Australia, United States, Italy, Argentina, Croatia, Russian Federation, Poland, Czechia, Belgium, France, Brazil, Austria, Denmark, Mexico, Serbia, Sweden, Ukraine
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)

Multiple Sclerosis

United Kingdom, Germany, Finland, Israel, Spain, Canada, France, Australia, Czechia, Austria, Sweden, Poland, Hungary, Italy
Novartis Pharmaceuticals

Recruiting

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (ALITHIOS)

Relapsing Multiple Sclerosis

United States, Australia, Austria, Belgium, Bulgaria, Canada, Germany, Hungary, Poland, Portugal, Russian Federation, Slovakia, Spain, Denmark, France, Japan, Israel, Taiwan, Turkey, Czechia, Argentina, Estonia, United Kingdom, India, C... and more
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
EMD Serono Research & Development Institute, Inc.

Terminated

Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

Relapsing Multiple Sclerosis

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Colombia, Croatia, Czechia, Estonia, Finland, France, Georgia, Germany, Hong Kong, Hungary, India, Israel, Italy, Korea, Republic of, M... and more
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); European Organisation for Research and Treatment... and other collaborators

Completed

Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States, Canada
NCIC Clinical Trials Group

Completed

Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

Canada, United States
Oncotherapeutics
Takeda

Completed

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Multiple Myeloma

United States
Eunice Kennedy Shriver National Institute of Child...

Unknown

Down Syndrome - Comparison of Screening Methods in the 1st and 2nd Trimesters

Down Syndrome | Chromosome Abnormalities

United States
Acorda Therapeutics
PRA Health Sciences

Completed

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis (M22)

Multiple Sclerosis

United States
Novartis Pharmaceuticals

Completed

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis (EPOC)

Relapsing Forms of Multiple Sclerosis

United States, Canada, Puerto Rico
Genzyme, a Sanofi Company
Bayer

Completed

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two (CARE-MS II)

Multiple Sclerosis, Relapsing-Remitting

Australia, Denmark, Canada, United States, Netherlands, Argentina, Austria, Belgium, Brazil, Croatia, Czech Republic, France, Germany, Israel, Italy, Mexico, Poland, Russian Federation, Serbia, Spain, Sweden, Ukraine, United Kingdom
European Organisation for Research and Treatment...

Completed

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

Lymphoma | Unspecified Childhood Solid Tumor, Protocol Specific | Myelodysplastic Syndromes | Leukemia | Unspecified Adult Solid Tumor, Protocol Specific | Infection | Multiple Myeloma and Plasma Cell Neoplasm | Fever, Sweats, and Hot Flashes | Bone Marrow Suppression

Switzerland, United States, Canada, United Kingdom, Belgium, Israel, Slovakia, Finland, Germany, France, Turkey, Czech Republic, Greece
Biogen

Completed

Plegridy Observational Program (POP)

Relapsing Forms of Multiple Sclerosis

United States, Italy, Switzerland, Canada, Australia, Germany, Spain, France, Portugal, Netherlands, United Kingdom, Denmark, Austria, Ireland
National Cancer Institute (NCI)

Recruiting

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
Novartis Pharmaceuticals

Completed

Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

Relapsing Forms of Multiple Sclerosis

Germany, South Africa, Italy, United States, Austria, Belgium, Czechia, Egypt, Hungary, Malaysia, Turkey, Spain, Australia, Canada, France, Israel, Netherlands, Switzerland, Greece, Korea, Republic of, Romania, Russian Federation, United... and more
Celgene

Completed

A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States, Canada, Germany, Spain, Denmark, Netherlands, Finland, Italy
Alnylam Pharmaceuticals

Completed

EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)

Acute Hepatic Porphyria

United States, Belgium, Bulgaria, France, Italy, Mexico, Spain, Taiwan, United Kingdom, Netherlands, Korea, Republic of, Switzerland, Czechia, Poland, Finland, Australia, Germany, Israel, Norway, South Africa
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Lynch Syndrome | Stage III Colon Cancer AJCC v8 | Colon Adenocarcinoma | DNA Repair Disorder

United States, Puerto Rico, Germany
Amgen

Completed

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ARROW2)

Relapsed or Refractory Multiple Myeloma

France, Czechia, Sweden, United States, Greece, Spain, Finland, Romania, Germany, Japan, Netherlands, Turkey, Austria, Bulgaria, Lithuania, Russian Federation, Slovakia
Swedish Orphan Biovitrum

Completed

Long Term Safety Study of Orfadin Treatment in HT-1 Patients in Standard Clinical Care (OPAL)

Hereditary Tyrosinemia, Type I

Belgium, Denmark, France, Germany, Austria, Czechia, Finland, Hungary, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Spain, Sweden, United Kingdom
Biogen

Completed

A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis

Multiple Sclerosis

United States
Sanofi

Completed

Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients (TERI-PRO)

Multiple Sclerosis

Finland, Belgium, Spain, Chile, Norway, Italy, United States, Austria, Canada, France, Germany, Greece, Sweden, United Kingdom
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma

Medulloblastoma | Nevoid Basal Cell Carcinoma Syndrome | Desmoplastic/Nodular Medulloblastoma | Medulloblastoma With Extensive Nodularity

United States, Canada, Puerto Rico, Australia
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries

Osteoporosis | Ovarian Carcinoma | Hereditary Breast and Ovarian Cancer Syndrome

United States
Merck KGaA, Darmstadt, Germany

Completed

Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX) (REFLEXION)

Multiple Sclerosis | Clinically Isolated Syndrome

Croatia, Bulgaria, France, Italy, Russian Federation, Spain, Estonia, Germany, Latvia, Poland, Romania, Argentina, Finland, Israel, Greece, Czech Republic, Slovakia, Austria, Belgium, Canada, Lebanon, Morocco, Portugal, Serbia
Merck KGaA, Darmstadt, Germany

Completed

REbif FLEXible Dosing in Early Multiple Sclerosis (MS) (REFLEX)

Multiple Sclerosis

Croatia, Bulgaria, France, Italy, Russian Federation, Spain, Turkey, Estonia, Germany, Latvia, Poland, Romania, Argentina, Israel, Portugal, Greece, Czech Republic, Slovakia, Serbia, Austria, Finland, Saudi Arabia, Belgium, Canada, Lebanon and more

Clinical Trials on Exostoses, Multiple Hereditary in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations